James M. Daly's most recent trade in Madrigal Pharmaceuticals Inc was a trade of 1,290 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 1,290 | 1,290 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 715 | 2,627 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 13,793 | 13,793 | - | - | Director Stock Options (Right to Buy) | |
| Acadia Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 9,387 | 0 | - | - | Restricted Stock Units | |
| Acadia Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2025 | 9,387 | 34,041 (0%) | 0% | - | Common Stock | |
| Acadia Pharmaceuticals Inc | James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 8,107 | 8,107 | - | - | Restricted Stock Units | |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 347.39 per share. | 27 Feb 2025 | 14,302 | 2,682 (0%) | 0% | 347.4 | 4,968,372 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 9,470 | 0 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 65.06 per share. | 27 Feb 2025 | 9,470 | 11,382 (0%) | 0% | 65.1 | 616,118 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 111.06 per share. | 27 Feb 2025 | 6,000 | 17,382 (0%) | 0% | 111.1 | 666,360 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 348.94 per share. | 27 Feb 2025 | 770 | 1,912 (0%) | 0% | 348.9 | 268,686 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 346.90 per share. | 27 Feb 2025 | 398 | 16,984 (0%) | 0% | 346.9 | 138,067 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 1,105 | 1,105 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 714 | 1,912 (0%) | 0% | 0 | Common Stock | |
| Acadia Pharmaceuticals Inc | James M. Daly | Director | 29 May 2024 | 15,959 | 15,959 | - | - | Director Stock Options (Right to Buy) | ||
| Acadia Pharmaceuticals Inc | James M. Daly | Director | 29 May 2024 | 9,387 | 9,387 | - | - | Restricted Stock Units | ||
| Acadia Pharmaceuticals Inc | James M. Daly | Director | 29 May 2024 | 6,652 | 24,654 (0%) | 0% | - | Common Stock | ||
| Acadia Pharmaceuticals Inc | James M. Daly | Director | 29 May 2024 | 6,652 | 0 | - | - | Restricted Stock Units | ||
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.45 per share. | 01 Apr 2024 | 20,000 | 21,198 (0%) | 0% | 100.5 | 2,009,000 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 105.08 per share. | 01 Apr 2024 | 10,912 | 12,110 (0%) | 0% | 105.1 | 1,146,633 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 10,912 | 0 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 256.50 per share. | 01 Apr 2024 | 7,401 | 8,565 (0%) | 0% | 256.5 | 1,898,371 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 255.64 per share. | 01 Apr 2024 | 6,809 | 15,966 (0%) | 0% | 255.6 | 1,740,630 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 244.19 per share. | 01 Apr 2024 | 6,279 | 4,989 (0%) | 0% | 244.2 | 1,533,286 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 257.30 per share. | 01 Apr 2024 | 3,604 | 4,961 (0%) | 0% | 257.3 | 927,302 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 244.89 per share. | 01 Apr 2024 | 2,991 | 1,998 (0%) | 0% | 244.9 | 732,480 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 105.08 per share. | 01 Apr 2024 | 1,577 | 22,775 (0%) | 0% | 105.1 | 165,711 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,577 | 10,912 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 258.28 per share. | 01 Apr 2024 | 1,460 | 3,501 (0%) | 0% | 258.3 | 377,094 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 243.26 per share. | 01 Apr 2024 | 842 | 11,268 (0%) | 0% | 243.3 | 204,821 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 262.00 per share. | 01 Apr 2024 | 800 | 2,501 (0%) | 0% | 262.0 | 209,604 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 246.30 per share. | 01 Apr 2024 | 557 | 1,441 (0%) | 0% | 246.3 | 137,187 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 265.49 per share. | 01 Apr 2024 | 500 | 1,472 (0%) | 0% | 265.5 | 132,743 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 264.89 per share. | 01 Apr 2024 | 351 | 1,972 (0%) | 0% | 264.9 | 92,977 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 266.91 per share. | 01 Apr 2024 | 274 | 1,198 (0%) | 0% | 266.9 | 73,132 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 259.11 per share. | 01 Apr 2024 | 200 | 3,301 (0%) | 0% | 259.1 | 51,822 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 248.45 per share. | 01 Apr 2024 | 200 | 1,198 (0%) | 0% | 248.5 | 49,690 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 263.31 per share. | 01 Apr 2024 | 178 | 2,323 (0%) | 0% | 263.3 | 46,870 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 247.02 per share. | 01 Apr 2024 | 43 | 1,398 (0%) | 0% | 247.0 | 10,622 | Common Stock |
| Halozyme Therapeutics Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 43.74 per share. | 11 Aug 2023 | 10,000 | 20,503 (0%) | 0% | 43.7 | 437,410 | Common Stock |
| Halozyme Therapeutics Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 43.71 per share. | 11 Aug 2023 | 10,000 | 30,503 (0%) | 0% | 43.7 | 437,110 | Common Stock |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 1,198 | 1,198 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc | James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 11,371 | 11,371 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 8,065 | 40,503 (0%) | 0% | 0 | Common Stock | |
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,470 | 9,470 | - | - | Stock Option (Right to Buy) | |
| Acadia Pharmaceuticals Inc | James M. Daly | Director | 07 Jun 2022 | 14,368 | 14,368 | - | - | Director Stock Options (Right to Buy) | ||
| Acadia Pharmaceuticals Inc | James M. Daly | Director | 07 Jun 2022 | 8,552 | 8,552 | - | - | Restricted Stock Units | ||
| Acadia Pharmaceuticals Inc | James M. Daly | Director | 22 Jun 2021 | 11,637 | 11,637 | - | - | Director Stock Options (Right to Buy) | ||
| Acadia Pharmaceuticals Inc | James M. Daly | Director | 22 Jun 2021 | 11,045 | 11,045 | - | - | Director Stock Options (Right to Buy) | ||
| Acadia Pharmaceuticals Inc | James M. Daly | Director | 22 Jun 2021 | 8,552 | 0 | - | - | Restricted Stock Units | ||
| Acadia Pharmaceuticals Inc | James M. Daly | Director | 22 Jun 2021 | 8,552 | 18,002 (0%) | 0% | - | Common Stock | ||
| Acadia Pharmaceuticals Inc | James M. Daly | Director | 22 Jun 2021 | 6,652 | 6,652 | - | - | Restricted Stock Units | ||
| Acadia Pharmaceuticals Inc | James M. Daly | Director | 22 Jun 2021 | 6,391 | 9,450 (0%) | 0% | - | Common Stock | ||
| Acadia Pharmaceuticals Inc | James M. Daly | Director | 22 Jun 2021 | 6,391 | 6,391 | - | - | Restricted Stock Units | ||
| Acadia Pharmaceuticals Inc | James M. Daly | Director | 22 Jun 2021 | 6,391 | 0 | - | - | Restricted Stock Units | ||
| Acadia Pharmaceuticals Inc | James M. Daly | Director | 22 Jun 2021 | 3,059 | 3,059 (0%) | 0% | - | Common Stock | ||
| Acadia Pharmaceuticals Inc | James M. Daly | Director | 22 Jun 2021 | 3,059 | 0 | - | - | Restricted Stock Units | ||
| Madrigal Pharmaceuticals Inc | James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 12,489 | 12,489 | - | - | Stock Option (Right to Buy) | |
| Halozyme Therapeutics Inc | James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 5,230 | 26,232 | - | 0 | Restricted Stock Unit | |
| Halozyme Therapeutics Inc | James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 40.41 per share. | 25 Nov 2020 | 10,363 | 21,002 (0%) | 0% | 40.4 | 418,800 | Common Stock |